恒瑞医药：HRS-3095片获药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of HRS-3095 tablets, a self-developed small molecule compound targeting immune cells for the treatment of allergic diseases [1] Group 1 - HRS-3095 tablets have shown promising preclinical results, effectively improving skin allergy symptoms in mice [1] - There are currently no approved drugs targeting the same indication (CSU) in both domestic and international markets [1] - The total research and development investment for the HRS-3095 project has reached approximately 16.03 million yuan [1]